|
|
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Number of employees : 33 625 people.
|
|
|
| 2019 | | USD (in Million) | % | | Pharmaceutical Products | 22,320 | 100% |
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | United States | 13,875 | 56.5% | 12,723 | 57% | -8.31% | | Europe | 4,231 | 17.2% | 3,765 | 16.9% | -11.02% | | Other Foreign Countries | 3,956 | 16.1% | 3,284 | 14.7% | -16.97% | | Japan | 2,494 | 10.2% | 2,548 | 11.4% | +2.16% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
957,068,598 |
955,049,005 |
99.8% |
487,000 |
0.1% |
99.8% |
|
|
|
| Name | Equities | % | | Lilly Endowment, Inc. | 110,702,343 |
11.6% | | Capital Research & Management Co. | 109,033,091 |
11.4% | | The Vanguard Group, Inc. | 65,354,284 |
6.83% | | The PNC Financial Services Group, Inc. | 50,000,000 |
5.23% | | PRIMECAP Management Co. | 37,975,324 |
3.97% | | SSgA Funds Management, Inc. | 34,935,118 |
3.65% | | Fidelity Management & Research Co. LLC | 28,083,352 |
2.94% | | Wellington Management Co. LLP | 25,317,842 |
2.65% | | BlackRock Fund Advisors | 19,675,191 |
2.06% | | State Farm Investment Management Corp. | 18,619,725 |
1.95% |
|
|
|
| Name | Equities | % | Valuation |
| Sigilon Therapeutics, Inc. (SGTX) | 2,744,443 | 9.09% | 131,815,597 USD | | Dicerna Pharmaceuticals, Inc. (DRNA) | 5,414,185 | 7.21% | 119,274,496 USD | | Avidity Biosciences, Inc. (RNA) | 2,169,396 | 5.78% | 55,362,986 USD | | Precision BioSciences, Inc. (DTIL) | 3,762,190 | 7.17% | 31,376,665 USD | | NextCure, Inc. (NXTC) | 2,088,859 | 7.58% | 22,768,563 USD | | AC Immune SA (ACIU) | 0 | 0.0000% | |
|
| Company contact information |
|
Eli Lilly & Co. Lilly Corporate Center Indianapolis, IN 46285 Phone : +1.317.276.2000 Web : http://www.lilly.com |
|
|
|
Eli Lilly to buy gene therapy developer Prevail in about $1 bln deal |
Sector Pharmaceuticals - NEC
Connections : Eli Lilly and Company |
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
